[PCN275] Sipuleucel-T (Provenge®): Autopsy of an Innovative Change of Paradigm in Cancer Treatment

[PCN275] Sipuleucel-T (Provenge®): Autopsy of an Innovative Change of Paradigm in Cancer Treatment

2015 Value in Health

Jaroslawski, S. | Caban, A. | Toumi, M. | Volume: 18, Issue: 7, Pages: A479,

Approved by the Food and Drug Administration (FDA) in 2010, sipuleucel-T was the first personalised “cancer vaccine” to treat prostate cancer in the metastatic, non-symptomatic population of 30,000 men in the US. Sipuleucel-T is prepared individually for each patient and infused in three sessions over one-month. In 2015, sipuleucel-T’s owner, Dendreon, filed for bankruptcy. This search aimed to review how this innovative product failed to achieve commercial success.

https://www.doi.org/10.1016/j.jval.2015.09.1294